CRC as First of Multiple Primary Malignancies Tied to Better Outcomes Than CRC as Only Malignancy

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 26, 2025.

via HealthDay

THURSDAY, June 26, 2025 -- Compared with colorectal cancer (CRC) presenting as an isolated primary or second primary malignancy, CRC presenting as the first of multiple primary malignancies less often presents at advanced stage and is associated with improved survival, according to a study published online June 17 in the Journal of the American College of Surgeons.

Anjelli Wignakumar, M.B.B.S., from Cleveland Clinic Florida in Weston, and colleagues examined features and outcomes of isolated primary CRC compared to CRC presenting in a sequence of multiple primary cancers in a retrospective cohort study. Patients were classified as CRC as the only malignancy (Group A, 424,920 patients), CRC as the first of multiple primary malignancies (Group B, 70,432 patients), and CRC as the second of multiple primary malignancies (Group C, 96,711 patients; 71.8, 11.9, and 16.3 percent, respectively).

The researchers found that patients in Group A were younger, had elevated pretreatment carcinoembryonic antigen, more frequent liver metastases, more frequent lung metastases, and systemic adjuvant treatments. More T4 tumors were included in Group A (14.5 percent versus 10.4 and 12.4 percent, respectively), and the group had less surgical treatments than Groups B and C (86.4 percent versus 94.8 and 88.1 percent, respectively). More men were included in Group B, and the group also had more left-sided CRC. Group C had more right-sided CRC. The longest overall survival and cancer-specific survival were seen for Group B (50.4 and 51.3 months, respectively).

"We expected isolated CRC patients to fare best, but patients with CRC diagnosed first, followed by another cancer had the best survival rates," Wignakumar said in a statement.

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-27 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords